Poor-risk germ cell tumors: Recent developments Journal Article

Authors: Dodd, P. M.; Motzer, R. J.; Bajorin, D. F.
Article Title: Poor-risk germ cell tumors: Recent developments
Abstract: Standard therapy for patients with poor-risk germ cell tumours remains four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, which cures approximately 50% of this patient population. Randomized trials of conventional-dose chemotherapy have failed to identify a regimen with superior efficacy to BEP. Preliminary data suggesting efficacy for high-dose chemotherapy with stem cell or autologous bone marrow transplantation as initial therapy for poor-risk patients. The recently developed International Germ Cell Concensus Classification provides a standard method for determining poor-risk status and should be uniformly applied for both clinical decision making and risk assignment in clinical trials.
Keywords: review; cisplatin; drug efficacy; antineoplastic agents; paclitaxel; drug megadose; antineoplastic agent; etoposide; drug administration schedule; tumor markers, biological; risk factors; tumor marker; ifosfamide; risk assessment; risk; testicular neoplasms; bleomycin; cancer classification; decision making; germ cell tumor; seminoma; non seminomatous germinoma; germinoma; humans; prognosis; human; male; priority journal
Journal Title: Urologic Clinics of North America
Volume: 25
Issue: 3
ISSN: 0094-0143
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 1998-08-01
Start Page: 485
End Page: 493
Language: English
PUBMED: 9728218
PROVIDER: scopus
DOI: 10.1016/s0094-0143(05)70038-0
Notes: Review -- Export Date: 12 December 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Dean Bajorin
    587 Bajorin
  2. Robert Motzer
    1043 Motzer
  3. Paul M Dodd
    14 Dodd